Loading clinical trials...
Loading clinical trials...
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure With Reduced Ejection Fraction
Conditions
Interventions
Dapagliflozin
Placebo
Locations
419
United States
Research Site
Fairhope, Alabama, United States
Research Site
Mobile, Alabama, United States
Research Site
Sheffield, Alabama, United States
Research Site
Bakersfield, California, United States
Research Site
Beverly Hills, California, United States
Research Site
Los Angeles, California, United States
Start Date
February 8, 2017
Primary Completion Date
July 17, 2019
Completion Date
July 17, 2019
Last Updated
September 1, 2020
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions